伴随着赴港潮的出现，越来越多A股公司正在登陆港股市场。 最新消息，A股龙头企业恒瑞医药（600276.SH）、宁德时代（300750.SZ）相继于5月5日、6日更新聆讯后资料集，意味着其已通过港交所聆讯，预计将很 快于港交所挂牌上市，而且有不少投资者预期这两家企业或刷新年内港股募资记录。 医药龙头赴港，业绩恢复增长 恒瑞医药早期业务以仿制药为主。然而，随着政策的变化，以及集采带来的冲击，仿制药市场的天花板日益显现。自2008年起，恒瑞医药开始向创新药研发 转型，2011年公司第一个创新药艾瑞昔布获批上市。 在经过多年的发展及持续高强度投入研发后，恒瑞医药的创新药已经覆盖传统优势的肿瘤领域。同时广泛布局了代谢和心血管疾病、免疫和呼吸系统疾病等 多个领域。根据弗若斯特沙利文的资料，这些主要治疗领域对应的全球制药市场规模占2023年全球制药市场总规模的57.4%，达8458亿美元，且预计2023年 至2028年复合年增长率达6.4%，超过同期全球制药市场5.7%的复合年增长率。 截至2025年4月23日，恒瑞医药拥有19款已上市的新分子实体创新药和逾90款处于临床及更后期阶段的新分子实体在研创新药。 值得一提的是， ...

Core Viewpoint - The dairy giant Yili (600887.SH) has ended its 30-year growth streak due to unprecedented industry pressures, with significant declines in revenue and profit expected in 2024 [1][2]. Financial Performance - Yili's 2024 revenue is projected to be 115.78 billion yuan, a year-on-year decline of 8.24%, while net profit is expected to drop to 8.45 billion yuan, down 18.9% [2]. - In Q4, Yili made a substantial impairment provision of 5.2 billion yuan, resulting in a quarterly loss of 2.42 billion yuan, further pressuring annual profits [3]. Impairment and Asset Valuation - A major component of the impairment was a goodwill write-down of 3.04 billion yuan related to the acquisition of Ausnutria (1717.HK), which has seen a significant decline in performance [4]. - Other impairment provisions included 1.23 billion yuan for inventory and 370 million yuan for fixed assets due to market demand changes and technological obsolescence [5]. Industry Challenges - The dairy industry has faced negative retail growth since 2022, with a 2.7% decline in overall sales in 2024, exacerbating supply-demand imbalances [9][10]. - Yili's liquid milk segment saw a revenue drop of 12.3% in 2024, with a decrease in both sales volume and price [11]. Market Strategy - To protect distributor profits, Yili began channel inventory clearance in Q2 2024, leading to a significant revenue drop of 16.5% in Q2, which narrowed to 6.7% in Q3 [12][13]. - By Q3, Yili completed channel clean-up, stabilizing sales during peak seasons [14]. Future Outlook - Yili anticipates a potential turnaround in 2025, with Q1 revenue showing a slight increase of 1.35% and net profit rising by 24.19% [17]. - The company remains cautious about demand recovery, projecting only a 2.8% increase in full-year revenue for 2025 [18]. Market Share and Growth Engines - Yili's liquid milk revenue has stagnated, with a slight increase to 85.54 billion yuan in 2023, but its market share in this segment is declining [21][22]. - Conversely, the infant formula segment is experiencing growth, with a 7.53% increase in revenue to 29.675 billion yuan in 2024, driven by rising birth rates [26][29]. Diversification Efforts - Yili is exploring diversification beyond dairy, including launching new tea and mineral water products, while also focusing on functional dairy products [40][43]. - The company is also investing in health-related sectors and has established a venture capital fund targeting high-tech innovations in the health industry [48].

医药生物 | 证券研究报告 — 调整盈利预测 2025 年 4 月 30 日 688085.SH 买入 原评级：买入 市场价格:人民币 17.47 板块评级:强于大市 股价表现 (%) 今年 至今 1 个月 3 个月 12 个月 绝对 (13.8) (3.5) (6.7) (7.1) 相对上证综指 (14.6) (1.6) (7.8) (12.7) 发行股数 (百万) 277.89 流通股 (百万) 248.45 总市值 (人民币 百万) 4,854.66 3 个月日均交易额 (人民币 百万) 35.04 主要股东 QM5 LIMITED 14.74 (19%) (10%) (2%) 7% 15% 24% Apr-24 Jun-24 Jul-24 Aug-24 Sep-24 Oct-24 Nov-24 Dec-24 Jan-25 Feb-25 Mar-25 Apr-25 三友医疗 上证综指 资料来源：公司公告， Wind ，中银证券 以 2025 年 4 月 29 日收市价为标准 相关研究报告 《三友医疗》20241105 《三友医疗》20240829 《三友医疗》20240816 中银国际证券股份有限公司 ...

Core Viewpoint - The company achieved steady performance improvement in Q1 2025, marking a "good start" with revenue and profit growth [2] Financial Performance - In Q1 2025, the company reported revenue of 6.246 billion yuan, a year-on-year increase of 5.09% [1] - The net profit attributable to shareholders was 842 million yuan, reflecting a year-on-year growth of 2.46% [1] Business Development - The company is focusing on solidifying its gypsum board and gypsum board+ business while driving growth in waterproof and coating sectors through both organic and external development [2] - The waterproof business achieved revenue of 1.054 billion yuan, with a year-on-year growth of 10.54%, and a net profit of 43 million yuan, up 19.89% [2] - The coating business saw significant growth, with revenue reaching 908 million yuan, a year-on-year increase of 111.44%, and a net profit of 44 million yuan, up 48.17% [2] - International business continued to perform well, with revenue increasing by 73% year-on-year and net profit rising by 143.08% [2] Profit Forecast and Investment Rating - The company is projected to achieve revenues of 28.820 billion yuan, 32.373 billion yuan, and 36.249 billion yuan from 2025 to 2027, with net profits of 4.462 billion yuan, 4.999 billion yuan, and 5.616 billion yuan respectively [3] - The current stock price corresponds to a PE ratio of 11.2, 10.0, and 8.9 for the years 2025, 2026, and 2027 [3] - The average valuation for comparable companies in 2025 is 23.1 times PE, and the company maintains an "overweight" rating [3]

Core Viewpoint - The company reported its Q1 2025 performance, showing a slight year-on-year growth in revenue and net profit, but significant quarter-on-quarter declines, aligning with market expectations [1]. Financial Performance - Q1 2025 revenue was 2.102 billion yuan, with a year-on-year increase of 3.5% - Net profit attributable to shareholders was 65 million yuan, up 5.2% year-on-year - Non-recurring net profit was 45 million yuan, down 3.9% year-on-year - Quarter-on-quarter comparisons showed a decline of 57.0% in revenue, 86.2% in net profit, and 88.0% in non-recurring net profit [1]. Development Trends - The box transformer business is expected to maintain steady growth, with a projected 700 million yuan order from Saudi Arabia likely to be fulfilled in Q2 2025 - The company anticipates accelerated growth in the box transformer business due to stable domestic market growth and higher gross margins from overseas orders - Charging business saw over 40% growth in charging volume in Q1 2025, with operational scale expanding and a continued trend of reduced losses expected - The sales and construction of charging piles were relatively flat in Q1 due to seasonal factors, but growth is anticipated in Q2 as the industry enters a construction peak [2]. Profitability and Cost Structure - Gross margin decreased by 1 percentage point year-on-year, attributed to a higher proportion of lower-margin box transformer business - Operating expense ratio increased by 0.5 percentage points year-on-year, with management expenses rising by 0.8 percentage points due to seasonal fluctuations in expense allocation [2]. Profit Forecast and Valuation - The company maintains net profit forecasts of 1.214 billion yuan for 2025 and 1.559 billion yuan for 2026 - Using the SOTP valuation method, the estimated value for the new energy charging business is 17.581 billion yuan, while the traditional power equipment business is valued at 14.248 billion yuan (15x 2025E P/E) - The target price is set at 30.15 yuan, indicating a potential upside of 23.1% [3].

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company is expected to achieve an EPS of 1.06/1.17 CNY for 2025-26, with a new forecast of 1.42 CNY for 2027. The target price is set at 56.18 CNY based on a PE ratio of 53 for 2025 [2] - The company reported a significant revenue increase of 22.63% year-on-year for 2024, reaching 27.985 billion CNY, and a net profit increase of 47.28%, totaling 6.337 billion CNY [9] - The company is actively advancing its internationalization efforts, with several products receiving FDA approval and significant licensing agreements contributing to revenue growth [9] Financial Information Summary - Revenue (in million CNY): - 2023A: 22,820 - 2024A: 27,985 (22.6% YoY growth) - 2025E: 31,684 (13.2% YoY growth) - 2026E: 35,553 (12.2% YoY growth) - 2027E: 40,900 (15.0% YoY growth) [4] - Net Profit (in million CNY): - 2023A: 4,302 - 2024A: 6,337 (47.3% YoY growth) - 2025E: 6,759 (6.7% YoY growth) - 2026E: 7,477 (10.6% YoY growth) - 2027E: 9,060 (21.2% YoY growth) [4] - EPS (in CNY): - 2023A: 0.67 - 2024A: 0.99 - 2025E: 1.06 - 2026E: 1.17 - 2027E: 1.42 [4] - Gross Margin: - 2023A: 84.6% - 2024A: 86.2% - 2025E: 84.5% - 2026E: 84.9% - 2027E: 85.4% [4] - Net Margin: - 2023A: 18.9% - 2024A: 22.6% - 2025E: 21.3% - 2026E: 21.0% - 2027E: 22.2% [4]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company is expected to achieve an EPS of 1.06/1.17 CNY for 2025-26, with a new forecast of 1.42 CNY for 2027. The target price is set at 56.18 CNY based on a PE ratio of 53 for 2025 [2] - The company reported a significant revenue increase of 22.63% year-on-year for 2024, reaching 27.985 billion CNY, and a net profit increase of 47.28%, totaling 6.337 billion CNY [9] - The company is actively advancing its internationalization efforts, with several products receiving FDA approval and significant licensing agreements contributing to revenue growth [9] Financial Information Summary - Revenue (in million CNY): - 2023A: 22,820 - 2024A: 27,985 (22.6% YoY growth) - 2025E: 31,684 (13.2% YoY growth) - 2026E: 35,553 (12.2% YoY growth) - 2027E: 40,900 (15.0% YoY growth) [4] - Net Profit (in million CNY): - 2023A: 4,302 - 2024A: 6,337 (47.3% YoY growth) - 2025E: 6,759 (6.7% YoY growth) - 2026E: 7,477 (10.6% YoY growth) - 2027E: 9,060 (21.2% YoY growth) [4] - EPS (in CNY): - 2023A: 0.67 - 2024A: 0.99 - 2025E: 1.06 - 2026E: 1.17 - 2027E: 1.42 [4] - Gross Margin: - 2023A: 84.6% - 2024A: 86.2% - 2025E: 84.5% - 2026E: 84.9% - 2027E: 85.4% [4] - Net Margin: - 2023A: 18.9% - 2024A: 22.6% - 2025E: 21.3% - 2026E: 21.0% - 2027E: 22.2% [4]

Core Insights - CITIC Securities reported a revenue of 63.79 billion yuan for 2024, a year-on-year increase of 6.20%, with a net profit of 21.70 billion yuan, up 10.06% [3][4] - The company’s investment business saw significant growth, with revenues reaching 24.04 billion yuan, a 23.95% increase year-on-year, while the investment banking segment experienced a decline of 35% [3][4][9] - Executive compensation was significantly reduced, with total remuneration for executives dropping nearly 70%, and the chairman's salary decreased by 2.7 million yuan [5][11][14] Financial Performance - CITIC Securities achieved a total operating income of 63.79 billion yuan, with a gross profit margin of 44.69% [4] - The brokerage business generated 16.56 billion yuan, up 27.54%, while asset management brought in 11.47 billion yuan, a 4.31% increase [4] - The company’s self-operated income reached 24 billion yuan, reflecting a 24% increase, attributed to a successful transformation in its investment strategy [9] Investment Banking and Market Activity - The investment banking sector faced challenges, with a 71.65% decline in A-share financing issuance, marking the lowest level since 2014 [6] - CITIC Securities led the industry in IPO income despite a 70% drop, earning 645 million yuan [6][7] - The company completed 22 IPO projects in the Hong Kong market, a 10-project increase from the previous year, and ranked second in underwriting scale [7][8] International Expansion - CITIC Securities International, a wholly-owned subsidiary, reported a net profit of 530 million USD, a 115% increase year-on-year [8] - The company completed 16 equity financing projects in overseas markets, with an underwriting scale of 864 million USD [7][8] Employee Compensation and Structure - The total compensation for executives was 28.76 million yuan, with the average salary for employees remaining stable at 780,400 yuan [12][14] - The number of employees at CITIC Securities remained relatively unchanged, with a total of 26,781 employees [12]

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 9.22 CNY, compared to the current stock price of 8.02 CNY [3][9]. Core Views - The company's performance in 2024 met expectations, with total revenue of 45.478 billion CNY, a year-on-year decrease of 3.39%, and a net profit of 3.52 billion CNY, a slight increase of 0.41% [1]. - The company is expected to see a recovery in profits in 2025, driven by improved domestic demand and continued growth in international markets and emerging businesses [9][10]. - The company has a strong focus on cash dividends and share buyback policies, with a planned dividend of 2.603 billion CNY for 2024, representing a dividend payout ratio of 73.95% [9]. Revenue and Profitability - The core business segments, including cranes and concrete machinery, generated revenues of 14.786 billion CNY and 8.013 billion CNY, respectively, with year-on-year declines of 23.35% and 6.8% [2]. - Emerging businesses, such as aerial work, earthmoving, and agricultural machinery, showed significant growth, with revenues of 6.833 billion CNY, 6.671 billion CNY, and 4.65 billion CNY, reflecting year-on-year increases of 19.74%, 0.34%, and 122.29% [2]. - The company's gross margin and net margin improved to 28.17% and 8.81%, respectively, with year-on-year increases of 0.63 percentage points and 0.8 percentage points [3]. Internationalization and Market Position - Domestic and overseas revenues were 22.098 billion CNY and 23.38 billion CNY, respectively, with year-on-year changes of -24.24% and +30.58%, marking a historical milestone where overseas revenue accounted for over 50% of total revenue [2]. - The company has established a strong market position in the domestic market for its main products and is rapidly expanding its overseas business, with export revenue growing by over 35% [2]. Financial Forecast - The company is projected to achieve revenues of 53.03 billion CNY, 62.52 billion CNY, and 73.79 billion CNY for 2024, 2025, and 2026, respectively, with growth rates of 16.6%, 17.9%, and 18% [9][11]. - Net profits are expected to reach 4.9 billion CNY, 6.12 billion CNY, and 7.6 billion CNY for the same years, with growth rates of 39.2%, 24.8%, and 24.2% [9][11].